Ma ke ʻano he lāʻau lapaʻau e pale ai i ka COVID_19,cephalanthineʻO ia ka mea hana nui i unuhi ʻia mai Stephania, kahi lāʻau lapaʻau kuʻuna Kina. Ua helu ʻia ka lāʻau lapaʻau patent Kina ma Kina a ma waho no nā makahiki he 40.
Ma Mei 10,2022, ua ʻike nā kānaka ʻepekema Kina i kahi lāʻau lapaʻau no covid_ 19 hou i loaʻa i nā patent noʻonoʻo ʻāina.
I ka puka ʻana mai o kēia ʻike, ua hauʻoli loa ia ma mua o ka hoʻopau ʻole ʻia ʻana o ka COVID 19. ʻOiai aia ka cepharanthine i ka noiʻi lāʻau lapaʻau a me ka hoʻomohala ʻana a ʻaʻole i hoʻohana ʻia i ka hoʻomaʻamaʻa lapaʻau, he nūhou maikaʻi loa ia no ʻO ke kūlana makemake ʻole o ka Covid 19. Eia kekahi, e like me nā hōʻike media, ua paʻi mua kekahi mau loea ʻAmelika i nā pepa i ka ʻepekema a hōʻoia ʻia ʻoi aku ka maikaʻi o ka ʻikepili noiʻi o ka cepharanthine ma mua o ka paxlovid, i ʻae ʻia no ka papa inoa. Ua launa pū ka ʻoihana lāʻau lapaʻau me ka US FDA e hana i kahi noiʻi hoʻokolohua lapaʻau e pili ana i ka mālama ʻana i ka COVID-19 me Cepharanthine.
ʻO Cepharanthine (CEP) kahi alkaloid kūlohelohe i loaʻa mai iā Stephania cepharantha Hayata a hōʻike ʻia he ʻano anti-inflammatory, antioxidative, immunomodulating, antiparasitic, a me nā waiwai antiviral.
ʻAʻole i ʻoi aku ka koʻikoʻi o kona hiki i ka therapeutic ma ke ʻano he antiviral agent ma mua o ka hakakā ʻana i ka COVID-19 i hoʻokumu ʻia e ka maʻi maʻi maʻi maʻi respiratory syndrome coronavirus type 2 (SARS-CoV-2).
Ma waena o nā mea nona nā patent, loaʻa iā mākou nā patent e pili anaʻO Cepharanthine.
ʻO Yunnan Hande Bio-tech Co., Ltd.ʻo ia ka mea hana a me ka mea hoʻolako me 28+ ʻike i ka hoʻokaʻawale kiʻekiʻe a me ka hoʻokaʻawale ʻana i nā mea kanu.ʻO Cepharanthinee like me ʻAukake 2011. ʻO kā mākou patent e wehewehe kikoʻī i ke ʻano o ka lawe ʻia ʻana o stephanine. Inā makemake ʻoe iā Cepharanthine ma kēia ʻano, mai kānalua, e ʻoluʻolu e kelepona koke iā mākou.
Ka manawa hoʻouna: Mei-16-2022